Iconic Therapeutics is a clinical-stage biopharmaceutical company built on scientific insight and expertise in tissue factor (TF) biology. We’re pioneering a new class of TF therapeutics that target diseases in which this protein is overexpressed, pursuing promising opportunities in ophthalmology and oncology, including wet age-related macular degeneration (AMD) and certain solid tumors.
Tissue Factor is a protein that plays a key role in inflammation and pathologic angiogenesis (the formation of abnormal new blood vessels), yet prior attempts to address this target have been hampered by inability to separate target engagement/inhibition from interference with normal blood coagulation. We have addressed the problem of safely targeting TF to disrupt those pathways and modify the underlying cause of the disease.
We’ve created a pipeline of two pre-clinical programs based on our TF platform, one in ophthalmology and one in oncology. Our lead program is a potential disease-modifying therapy for wet AMD. Leveraging our experiences from our first-generation program (ICON-1), we are planning to complete IND-enabling studies in 2019. Our second program in preclinical development for solid tumors has shown excellent activity in difficult to treat xenografts and PDX models. We’re planning to initiate IND-enabling studies in 2019.
We have a broad intellectual property portfolio exclusively licensed from Yale University, one of the first institutions to have cloned and characterized TF, as well as a next-generation set of anti-TF monoclonal antibodies we have discovered in-house.